Company Description: Vyro is a worldwide pioneer in the development of therapies and drug-delivery viral vectors based on Zika. Its technology is grounded on genetically modified Zika virus for (i) the treatment of CNS tumors, and (ii) viral vector for gene delivery, with solid differentials: Oncolytic therapy: • High efficacy: viral tropism for tumor stem cells present in cancer; • Lower toxicity: selective virus for tumor cells and viral inhibition system in normal cells; and • Lower cost than existing technologies: no need for specialized equipment. Viral vector: • Safety: low pathogenic and no-replicative viral vector with less inflammatory response • Stability: controlled transgene expression in a caping independent process. • Controlled cell tropism with a natural and controlled tropism to the brain and eyes; • Payload: Transgene sequence carrying capability up to 10 kb.